FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095549649> ?p ?o ?g. }

• W3095549649 endingPage "16" @default.
• W3095549649 startingPage "15" @default.
• W3095549649 abstract "INTRODUCTION: Complement factor D is the rate-limiting enzyme for activation of the complement alternative pathway (AP). Targeting factor D is therefore an attractive therapeutic strategy for treatment of AP-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and atypical hemolytic uremic syndrome. BCX9930 is a potent and selective orally bioavailable inhibitor of factor D in development for the treatment of PNH and other complement-mediated diseases. PNH is an acquired, chronic, non-malignant disorder of hematopoietic stem cells that is characterized by clonal deficiency of AP regulatory proteins CD55 and CD59, resulting in dysregulated AP amplification, opsonization, membrane attack complex (MAC) formation, and hemolysis. The approved intravenously (IV) administered C5 inhibitors eculizumab and ravulizumab inhibit MAC formation and intravascular hemolysis, but do not inhibit opsonization, leading to extravascular hemolysis and potentially incomplete treatment response. Inhibition of factor D is expected to prevent both intravascular and extravascular hemolysis in PNH, a distinct advantage over currently available parenteral therapies. METHODS: This abstract describes preliminary data in healthy subjects enrolled in the single ascending dose (SAD) and multiple ascending dose (MAD) evaluations of Study BCX9930-101 (NCT04330534), an ongoing first in human (FIH) study that includes randomized, double-blind, placebo-controlled evaluations of the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BCX9930 in healthy subjects. Safety and tolerability are evaluated via clinical and laboratory monitoring. Plasma concentrations of BCX9930 are measured using a validated liquid chromatography-dual mass spectrometry (LC/MS/MS) assay; PD effects are assessed using multiple assays, including inhibition of AP activity in the AP-specific Wieslab (AP-W) and AP Hemolysis ([AP-H], lysis of rabbit red blood cells [RBCs] by human serum) assays. RESULTS: To date, 48 subjects have been enrolled into 6 SAD cohorts (n = 6 BCX9930, n = 2 placebo per cohort), with doses ranging from 10 to 1200 mg. Sixty subjects have been enrolled into 5 MAD cohorts (n = 10 BCX9930, n = 2 placebo per cohort), with doses ranging from 50 mg every 12 hours (Q12h) to 400 mg Q12h. The mean age of all enrolled subjects was 34.3 years and 50.9% were male. BCX9930 was safe and generally well-tolerated at all doses evaluated. There were no serious adverse events or dose-related safety signals. Mild headache was the most frequent treatment-emergent adverse event and showed no correlation with dose. A benign maculopapular exanthem attributed to study drug was observed following MAD administration. These events were mild or moderate in severity and resolved in a median of 5 days. BCX9930 exposure was approximately linear and dose-proportional across all evaluated SAD and MAD doses. Mean BCX9930 concentrations at 12 hours post dose were ≥ 8 to 10 times the factor D half-maximal effective concentration (EC50) for SAD doses ≥ 300 mg and for MAD doses ≥ 100 mg Q12h at steady-state. Rapid, dose-dependent AP suppression was observed following SAD and MAD, as measured by the AP-W and AP-H assays (Figure 1). AP suppression &gt; 98% was observed in both assays at steady state for MAD doses ≥ 200 mg Q12h. Duration of complete suppression increased with dose and was ≥ 12 hours for MAD doses ≥ 200 mg Q12h. Doses ≥ 200 mg Q12h showed greater, more durable, and more consistent inhibition across subjects compared with doses ≤ 100 mg Q12h. PK/PD modeling of AP-H and AP-W demonstrates a clear concentration-response, with estimated EC50 values between 21.7 and 40.7 nM. These estimates are consistent with the in vitro IC50 for inhibition of proteolytic activity against the natural substrate C3bB of 28.1 nM. CONCLUSIONS: BCX9930 is a potent and selective orally bioavailable inhibitor of human complement factor D. In this preliminary analysis of an ongoing FIH study, BCX9930 displayed a promising safety and tolerability profile. Exposure was approximately linear and dose-proportional across a wide dose range, and complete and durable suppression of the AP was achieved. Together, these findings support further evaluation of BCX9930 in patients with PNH and other AP-mediated diseases. Disclosures Davidson: BioCryst Pharmaceuticals, Inc.:Current Employment.Mathis:BioCryst Pharmaceuticals, Inc.:Current Employment.Mair:Quotient Sciences:Current Employment.Gesty-Palmer:BioCryst Pharmaceuticals, Inc.:Current equity holder in publicly-traded company, Ended employment in the past 24 months.Cornpropst:BioCryst Pharmaceuticals, Inc.:Current Employment.Sheridan:BioCryst Pharmaceuticals, Inc.:Current Employment.Chen:BioCryst Pharmaceuticals, Inc.:Current Employment.Reynolds:BioCryst Pharmaceuticals, Inc.:Current Employment.Parker:BioCryst Pharmaceuticals, Inc.:Current Employment.Babu:BioCryst Pharmaceuticals, Inc.:Current Employment." @default.
• W3095549649 created "2020-11-09" @default.
• W3095549649 creator A5000720742 @default.
• W3095549649 creator A5002112371 @default.
• W3095549649 creator A5008194329 @default.
• W3095549649 creator A5026334448 @default.
• W3095549649 creator A5040769149 @default.
• W3095549649 creator A5051558775 @default.
• W3095549649 creator A5052024523 @default.
• W3095549649 creator A5061355653 @default.
• W3095549649 creator A5080405524 @default.
• W3095549649 creator A5083420537 @default.
• W3095549649 date "2020-11-05" @default.
• W3095549649 modified "2023-10-12" @default.
• W3095549649 title "BCX9930, an Oral Factor D Inhibitor, for the Potential Treatment of Alternative Pathway Mediated Diseases: Interim Results of a Phase 1 Study in Healthy Subjects" @default.
• W3095549649 doi "https://doi.org/10.1182/blood-2020-138475" @default.
• W3095549649 hasPublicationYear "2020" @default.
• W3095549649 type Work @default.
• W3095549649 sameAs 3095549649 @default.
• W3095549649 citedByCount "3" @default.
• W3095549649 countsByYear W30955496492022 @default.
• W3095549649 crossrefType "journal-article" @default.
• W3095549649 hasAuthorship W3095549649A5000720742 @default.
• W3095549649 hasAuthorship W3095549649A5002112371 @default.
• W3095549649 hasAuthorship W3095549649A5008194329 @default.
• W3095549649 hasAuthorship W3095549649A5026334448 @default.
• W3095549649 hasAuthorship W3095549649A5040769149 @default.
• W3095549649 hasAuthorship W3095549649A5051558775 @default.
• W3095549649 hasAuthorship W3095549649A5052024523 @default.
• W3095549649 hasAuthorship W3095549649A5061355653 @default.
• W3095549649 hasAuthorship W3095549649A5080405524 @default.
• W3095549649 hasAuthorship W3095549649A5083420537 @default.
• W3095549649 hasConcept C111684460 @default.
• W3095549649 hasConcept C112705442 @default.
• W3095549649 hasConcept C126322002 @default.
• W3095549649 hasConcept C159654299 @default.
• W3095549649 hasConcept C189446657 @default.
• W3095549649 hasConcept C197934379 @default.
• W3095549649 hasConcept C203014093 @default.
• W3095549649 hasConcept C2777346216 @default.
• W3095549649 hasConcept C2777991916 @default.
• W3095549649 hasConcept C2778375690 @default.
• W3095549649 hasConcept C2779902561 @default.
• W3095549649 hasConcept C71924100 @default.
• W3095549649 hasConcept C98274493 @default.
• W3095549649 hasConceptScore W3095549649C111684460 @default.
• W3095549649 hasConceptScore W3095549649C112705442 @default.
• W3095549649 hasConceptScore W3095549649C126322002 @default.
• W3095549649 hasConceptScore W3095549649C159654299 @default.
• W3095549649 hasConceptScore W3095549649C189446657 @default.
• W3095549649 hasConceptScore W3095549649C197934379 @default.
• W3095549649 hasConceptScore W3095549649C203014093 @default.
• W3095549649 hasConceptScore W3095549649C2777346216 @default.
• W3095549649 hasConceptScore W3095549649C2777991916 @default.
• W3095549649 hasConceptScore W3095549649C2778375690 @default.
• W3095549649 hasConceptScore W3095549649C2779902561 @default.
• W3095549649 hasConceptScore W3095549649C71924100 @default.
• W3095549649 hasConceptScore W3095549649C98274493 @default.
• W3095549649 hasIssue "Supplement 1" @default.
• W3095549649 hasLocation W30955496491 @default.
• W3095549649 hasOpenAccess W3095549649 @default.
• W3095549649 hasPrimaryLocation W30955496491 @default.
• W3095549649 hasRelatedWork W1975172184 @default.
• W3095549649 hasRelatedWork W2029220893 @default.
• W3095549649 hasRelatedWork W2070878239 @default.
• W3095549649 hasRelatedWork W2098778053 @default.
• W3095549649 hasRelatedWork W2465204721 @default.
• W3095549649 hasRelatedWork W2961142813 @default.
• W3095549649 hasRelatedWork W2982422691 @default.
• W3095549649 hasRelatedWork W3004435019 @default.
• W3095549649 hasRelatedWork W3096753583 @default.
• W3095549649 hasRelatedWork W4283518705 @default.
• W3095549649 hasVolume "136" @default.
• W3095549649 isParatext "false" @default.
• W3095549649 isRetracted "false" @default.
• W3095549649 magId "3095549649" @default.
• W3095549649 workType "article" @default.